2024-08-13T15:21:03+00:00 2023-09-30 346565596 ERNST & YOUNG US LLP 18101 VON KARMAN AVENUE IRVINE CA 92612 990 2022-10-01 753065445 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE TRAN 6023438400 445 N 5TH STREET 600 PHOENIX AZ 85004 JEFFREY M TRENT PHD BOARD MEMBER/PRES/SCIENCE DIR. 2024-08-13 true Kara Adams P00023315 9497942300 2024-07-31 2022 2024-08-08 14:25:15Z JEFFREY M TRENT PHD 445 N 5TH STREET 600 PHOENIX AZ 85004 58074297 false X WWW.TGEN.ORG X 2002 AZ PLEASE SEE SCHEDULE O 12 10 496 50 0 0 33269986 40082268 14701502 11607330 3778567 2399109 -3960559 -4469866 47789496 49618841 328217 1802912 0 0 41065789 45831709 0 0 33110939 33509852 74504945 81144473 -26715449 -31525632 174203210 145155331 57234236 54726440 116968974 90428891 X PLEASE SEE SCHEDULE O false false 6691636 0 2277226 PLEASE SEE SCHEDULE O. 6176622 0 480786 PLEASE SEE SCHEDULE O. 5092274 0 1806920 PLEASE SEE SCHEDULE O. 35325500 1802912 7042398 PLEASE SEE SCHEDULE O. 35325500 1802912 7042398 53286032 true true false true false false false false true true false true true true true false true false false true false false false false false false true false true false false false false false false false false false false false false true true true true false false true 94 0 true 496 true false false false false false false false false false false true false X 12 10 false false false false true true true true false false false true true true true true true true true false X TRACY KARNS 6023438415 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 JEFFREY M TRENT PHD BOARD MEMBER/PRES/SCIENCE DIR. 39.0 1.0 X X 0 1194012 258282 ROBERT W STONE BD & VICE CHRM/COH CEO & PRES. 1.0 61.0 X X 0 4316431 814563 WILLIAM J POST BOARD MEMBER/CHAIRMAN 1.0 11.0 X X 0 0 0 ANTHONY SCOTT BOARD MEMBER 1.0 0 X 0 0 0 BENNETT DORRANCE BOARD MEMBER 1.0 1.0 X 0 0 0 DAVID J GULLEN MD BOARD MEMBER 1.0 0 X 0 0 0 KAREN QUINTOS BOARD MEMBER 1.0 0 X 0 0 0 MARILYN QUAYLE BOARD MEMBER 1.0 0 X 0 0 0 PAMELA KEHALY BOARD MEMBER 1.0 0 X 0 0 0 RICHARD SILVERMAN BOARD MEMBER 1.0 0 X 0 0 0 SHARON HARPER BOARD MEMBER 1.0 0 X 0 0 0 TERRY PEETS BOARD MEMBER 1.0 0 X 0 0 0 CRISTIN O'CALLAHAN SECRETARY/COH GENERAL COUNSEL 1.0 63.0 X 0 990340 190870 JAMES LOWEY CHIEF INFORMATION OFFICER (PT YR) 40.0 0 X 235100 0 17239 JENNIFER A PARKHURST TREASURER/COH CFO (PT YR) 1.0 63.0 X 0 2064500 143720 KEVIN CAMPBELL CHIEF INFORMATION OFFICER (PT YR) 40.0 0 X 272043 0 24485 MANUEL ESTRADA CFO/ASSISTANT TREASURER 39.0 1.0 X 423372 0 24929 STEPHANIE MCRAE GENERAL COUNSEL/ASST SECRETARY 40.0 0 X 405364 0 25198 TERESA BURLESON CHIEF OPERATING OFFICER 39.0 1.0 X 693598 0 25197 DANIEL VON HOFF PHYSICIAN IN CHIEF 40.0 0 X 807772 0 23197 KENDALL JENSEN DEPUTY DIR. OF RESEARCH RES. 40.0 0 X 417331 0 25983 MICHAEL BERENS DEPUTY DIRECTOR OF RESEARCH 40.0 0 X 460036 0 29806 SUNIL SHARMA DEPUTY DIR OF CLINIC. SCIENCES 40.0 0 X 626245 0 25431 AHUVA ODENHEIMER BIOINFORMATICIAN 0 X 584939 0 0 BRADON MCDONALD COMPUTATIONAL SCIENTIST II 40.0 0 X 1364858 0 0 MARIA PERDIGONES STAFF SCIENTIST 40.0 0 X 1169878 0 0 TANIA CONTENTE-CUOMO PROGRAM MANAGER - BLOOD LIQUID BIOPSY 40.0 0 X 1938394 0 23833 TIMOTHY MCDANIEL SR. VP OF EMERG OPP 40.0 0 X 701927 0 0 GREGORY D SCHETINA FORMER OFFICER 1.0 0.0 X 0 183976 0 10100857 8749259 1652733 108 false true false ERNST & YOUNG US LLP 200 Plaza Drive Ste 2222 Secaucus NJ 07094 PROFESSIONAL SERVICES 342730 FIRSTSTRATEGIC 300 W CLARENDON AVE SUITE 460 PHOENIX AZ 85013 CONSULTING SERVICES 216000 IAA CONSULTING LLC 38 DUBLIN ROAD SKILLMAN NJ 08558 CONSULTING SERVICES 124575 MUHAMMED MURTAZA 1002 WINDING WAY MIDDLETON WI 53562 PROFESSIONAL SERVICES 120000 4 0 0 0 16456352 17493352 6132564 40082268 RESEARCH CONTRACTS 541711 11607330 11607330 0 0 0 0 0 0 11607330 1083911 1083911 3066679 7536545 -4469866 0 -4469866 -4469866 2154109 80000 838334 80577 1315775 -577 1315198 1315198 0 0 0 0 0 49618841 11607330 0 -2070757 1802912 1802912 0 0 0 0 0 0 5279740 2776696 2503044 0 0 0 0 0 33613240 20017869 13595371 0 1659926 973330 686596 0 2674354 1588852 1085502 0 2604449 1500464 1103985 0 0 0 0 0 821163 398223 422940 0 452120 9043 443077 0 129600 0 129600 0 0 0 0 0 0 0 7967658 6134211 1833447 0 742663 556997 185666 0 9716628 9101499 615129 0 3347728 2772056 575672 0 0 0 0 0 705016 232655 472361 0 431861 199364 232497 0 0 0 0 0 482405 85948 396457 0 202204 135477 66727 0 0 0 0 0 7985533 4791320 3194213 0 145315 40055 105260 0 DUES AND SUBSCRIPTIONS 173166 38110 135056 0 RECRUITMENT 97565 73174 24391 0 RELOCATION 25041 18781 6260 0 BAD DEBT EXPENSE 38996 38996 0 0 45190 0 45190 0 81144473 53286032 27858441 0 0 0 0 0 15119862 12335892 10356014 4697537 9237581 10001754 409085 406785 25000 0 0 0 0 0 0 0 1847445 2774586 94423387 38230147 56200583 56193240 0 0 0 61414092 41118193 8276723 7791744 11316825 9835600 174203210 145155331 9093772 8165819 0 0 1909599 1611782 0 0 50000 0 0 0 45095201 43674178 0 0 1085664 1274661 57234236 54726440 X 110923289 84763320 6045685 5665571 0 0 0 0 0 0 116968974 90428891 174203210 145155331 -31525632 4985549 0 X false true X true true true X 62343578 54124639 36879938 33269986 40082268 226700409 0 0 62343578 54124639 36879938 33269986 40082268 226700409 562413 226137996 3155820 3056541 52873472 3982551 4150590 67218974 0 0 0 0 0 0 0 293919383 94061751 0.7694 0.7390 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false false false true 129600 129600 false Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) USES A THIRD PARTY COMMUNICATIONS AND PUBLIC AFFAIRS FIRM TO COORDINATE LOBBYING EFFORTS ON BEHALF OF TGEN THROUGH COMMUNICATIONS TO LOCAL GOVERNMENT, LEGISLATIVE AND FEDERAL OFFICIALS AND COMMUNITY LEADERS ON TGEN ACTIVITIES. 5611952 172948 416368 691779 5509489 6833524 171950 -815957 577565 5611952 6696827 173542 517109 553954 6833524 6186285 378481 419824 287763 6696827 5088052 1373720 227248 502735 6186285 0.0 0.0113 0.9887 false true true 49269927 11802914 37467013 4405751 2882466 1523285 36026756 20466431 15560325 4720953 3078336 1642617 56193240 COH LT Investment 41118193 F 41118193 DUE FROM RELATED ORGANIZATIONS 8560939 EMPLOYEE 457 (B) PLAN ASSETS 1274661 9835600 0 DUE TO EMPLOYEE 457 (B) PLAN 1274661 1274661 X Schedule D, Part V, Line 4 Intended uses of endowment funds TGEN FOUNDATION CLASSIFIES AS PERMANENTLY RESTRICTED NET ASSETS (1) THE ORIGINAL VALUE OF THE GIFT DONATED TO THE PERMANENT ENDOWMENT, (2) THE ORIGINAL VALUE OF SUBSEQUENT GIFTS DONATED TO THE PERMANENT ENDOWMENT, AND (3) ACCUMULATIONS TO THE PERMANENT ENDOWMENT MADE IN ACCORDANCE WITH THE DIRECTION OF THE APPLICABLE DONOR GIFT INSTRUMENT. TGEN FOUNDATION HAS A TEMPORARILY RESTRICTED ASSET WHICH HAS BEEN DESIGNATED TO SUPPORT SUMMER INTERNS EACH YEAR AT TGEN. TGEN FOUNDATION'S POLICY FOR APPROPRIATING THE DISTRIBUTION OF ITS SUMMER INTERNSHIP PROGRAM ENDOWMENT HAS BEEN DESIGNED TO SUPPORT A GRANT TO TGEN FOR AN INTERN EACH YEAR FOR 25 YEARS. THE FOUNDATION CONSIDERED THE LONG-TERM EXPECTED RETURN ON ITS ENDOWMENT. TGEN FOUNDATION HAS A RESTRICTED ASSET FOR THE ESTABLISHMENT OF AN ENDOWED CHAIR IN BRAIN CANCER RESEARCH. TGEN FOUNDATION ALSO HAS A RESTRICTED ASSET WHICH ALLOWS THEM TO USE ANY INVESTMENT INCOME FOR OPERATING EXPENSES. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE AND ITS AFFILIATES ARE INCLUDED IN THE CONSOLIDATED AUDITED FINANCIAL STATEMENTS OF CITY OF HOPE (FEIN: 95-3435919, A RELATED TAX-EXEMPT ENTITY) WHICH INCLUDES CITY OF HOPE, CITY OF HOPE NATIONAL MEDICAL CENTER, THE MEDICAL FOUNDATION, BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE AND ITS AFFILIATES, SOUTHERN CALIFORNIA RADIATION ONCOLOGY, LLC, ACCESSHOPE, LLC, CITY OF HOPE AUXILIARIES (AUXILIARIES) AND COH HOLDCO, INC. BELOW IS THE FOOTNOTE ADDRESSING THE ORGANIZATION'S LIABILITY FOR UNCERTAIN TAX POSITIONS. ASC 740, INCOME TAXES, CLARIFIES THE ACCOUNTING FOR INCOME TAXES BY PRESCRIBING A MINIMUM RECOGNITION THRESHOLD THAT A TAX POSITION IS REQUIRED TO MEET BEFORE BEING RECOGNIZED IN THE FINANCIAL STATEMENTS. ASC 740 ALSO PROVIDES GUIDANCE ON DE-RECOGNITION, MEASUREMENT, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE, AND TRANSITION. THE GUIDANCE CONTAINED IN ASC 740 IS APPLICABLE TO PASS-THROUGH ENTITIES AND TAX-EXEMPT ORGANIZATIONS. CITY OF HOPE HAS NO SIGNIFICANT UNCERTAIN TAX POSITIONS OR TAX LIABILITY FOR TAX BENEFITS, INTEREST, OR PENALTIES ACCRUED AS OF SEPTEMBER 30, 2023 OR 2022. East Asia and the Pacific 0 0 Program Services RESEARCH SERVICES 185157 Middle East and North Africa 0 0 Program Services RESEARCH SERVICES 97610 Europe (Including Iceland and Greenland) 0 0 Program Services RESEARCH SERVICES 554599 North America (Canada & Mexico only) 0 0 Program Services RESEARCH SERVICES 129707 South America 0 0 Program Services RESEARCH SERVICES 8904 South Asia 0 0 Program Services RESEARCH SERVICES 169279 0 0 0 0 0 0 1145256 0 1145256 false false false false false false Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; MIDDLE EAST AND NORTH AFRICA-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; SOUTH AMERICA-Accrual; SOUTH ASIA-Accrual true CITY OF HOPE NATIONAL MEDICAL CENTER 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 501(C)(3) 1802912 Project Support 1 0 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds. TGen monitors its grants to ensure such grants are used for proper purposes via regular financial reviews with the grantee. Progress against goals is also reviewed with the grantees regularly. false true false false false false false true false ROBERT W STONE BD & VICE CHRM/COH CEO & PRES. 0 1934491 0 2208096 0 173844 0 773740 0 40823 0 5130994 0 571620 JEFFREY M TRENT PHD BOARD MEMBER/PRES/SCIENCE DIR. 0 844157 0 232127 0 117728 0 226158 0 32124 0 1452294 0 216254 GREGORY D SCHETINA FORMER OFFICER 0 9800 0 0 0 174176 0 0 0 0 0 183976 0 174176 TERESA BURLESON CHIEF OPERATING OFFICER 542595 0 149741 0 1262 0 12173 0 13024 0 718795 0 0 0 MANUEL ESTRADA CFO/ASSISTANT TREASURER 355750 0 66360 0 1262 0 9617 0 15312 0 448301 0 0 0 JAMES LOWEY CHIEF INFORMATION OFFICER (PT YR) 231625 0 2500 0 975 0 9280 0 7959 0 252339 0 0 0 STEPHANIE MCRAE GENERAL COUNSEL/ASST SECRETARY 302522 0 80000 0 22842 0 11543 0 13655 0 430562 0 0 0 CRISTIN O'CALLAHAN SECRETARY/COH GENERAL COUNSEL 0 578260 0 373230 0 38850 0 144810 0 46060 0 1181210 0 35344 JENNIFER A PARKHURST TREASURER/COH CFO (PT YR) 0 902290 0 1060305 0 101905 0 92460 0 51260 0 2208220 0 216416 KEVIN CAMPBELL CHIEF INFORMATION OFFICER (PT YR) 210931 0 60000 0 1112 0 11297 0 13188 0 296528 0 0 0 MICHAEL BERENS DEPUTY DIRECTOR OF RESEARCH 385325 0 50000 0 24711 0 16551 0 13255 0 489842 0 0 0 KENDALL JENSEN DEPUTY DIR. OF RESEARCH RES. 331069 0 85000 0 1262 0 8386 0 17597 0 443314 0 0 0 SUNIL SHARMA DEPUTY DIR OF CLINIC. SCIENCES 528403 0 75000 0 22842 0 9982 0 15449 0 651676 0 0 0 DANIEL VON HOFF PHYSICIAN IN CHIEF 764991 0 38863 0 3918 0 10649 0 12548 0 830969 0 0 0 TANIA CONTENTE-CUOMO PROGRAM MANAGER - BLOOD LIQUID BIOPSY 104982 0 1832809 0 603 0 12199 0 11634 0 1962227 0 0 0 BRADON MCDONALD COMPUTATIONAL SCIENTIST II 0 0 1364858 0 0 0 0 0 0 0 1364858 0 0 0 MARIA PERDIGONES STAFF SCIENTIST 0 0 1169878 0 0 0 0 0 0 0 1169878 0 0 0 AHUVA ODENHEIMER BIOINFORMATICIAN 0 0 584939 0 0 0 0 0 0 0 584939 0 0 0 TIMOTHY MCDANIEL SR. VP OF EMERG OPP 0 0 701927 0 0 0 0 0 0 0 701927 0 0 0 Schedule J, Part I, Line 3 Arrangement used to establish the top management official's compensation THE PRESIDENT OF TGEN IS COMPENSATED BY ITS RELATED ORGANIZATION, CITY OF HOPE, WHICH ALSO DETERMINES THE METHODS FOR ESTABLISHING COMPENSATION. Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan THE CITY OF HOPE HAS A NON QUALIFIED SECTION 457(F) EXECUTIVE SUPPLEMENTAL ACCUMULATION PLAN THAT IS DESIGNED AND MAINTAINED TO PROVIDE A SELECT GROUP OF MANAGEMENT OR HIGHLY COMPENSATED EMPLOYEES WITH DEFERRED COMPENSATION. THE PLAN VESTS AFTER THREE (3) FISCAL YEARS OF SERVICE AND THE VESTED TOTALS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN (B) (III). PRIOR TO VESTING, THE ANNUAL CONTRIBUTION AMOUNTS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN (C). PURSUANT TO THE PLAN DOCUMENT, VESTED PARTICIPANTS ARE ENTITLED TO WITHDRAW FROM THEIR VESTED ACCOUNT AN AMOUNT EQUAL TO THE FEDERAL, STATE, LOCAL AND FICA TAXES THEY OWE. THESE AMOUNTS ARE REMITTED TO THE APPROPRIATE TAXING AUTHORITIES ON BEHALF OF THE PARTICIPANTS. For CALENDAR YEAR 2022, THE FOLLOWING INDIVIDUALS WITHDREW THE REFERENCED AMOUNTS TO COVER SUCH TAXES: Robert W. Stone - $42,937 Jennifer Parkhurst - $23,879 Additionally, the following individuals received payments from the plan during the calendar year: GREGORY D. SCHETINA - $174,175 Schedule J, Part I, Line 7 Non-fixed payments SOME OF TGEN'S OFFICERS AND KEY EMPLOYEES LISTED IN PART VII WERE PAID BONUSES WHICH WERE BASED ON ACCOMPLISHMENTS OF SPECIFIC MILESTONES AND/OR PERFORMANCE METRICS, AS APPROVED BY THE TGEN BOARD OF DIRECTORS. Schedule J, Part II SCHEDULE J, PART II SOME OF TGEN'S OFFICERS AND KEY EMPLOYEES LISTED IN PART VII HAVE RETENTION AGREEMENTS THROUGH 2022 AND 2021. AMOUNTS ACCRUED BY TGEN DURING CALENDAR YEAR 2022 UNDER THESE AGREEMENTS HAVE BEEN REPORTED IN SCHEDULE J, PART II, COLUMN (C) AS DEFERRED COMPENSATION. Form 990, Part I, Line 1 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) IS A NONPROFIT BIOMEDICAL RESEARCH INSTITUTE FOCUSED ON DEVELOPING EARLIER AND SMARTER TREATMENTS BY EMPLOYING INNOVATIVE ADVANCES ARISING FROM THE HUMAN GENOME PROJECT AND APPLYING THEM TO THE DEVELOPMENT OF DIAGNOSTICS, PROGNOSTICS AND THERAPIES FOR CANCER, NEUROLOGICAL DISORDERS, DIABETES AND OTHER COMPLEX DISEASES. Form 990, Part III, Line 4a PROGRAM SERVICE DESCRIPTION INTEGRATED CANCER THE DIVISION OF INTEGRATED CANCER GENOMICS (ICG) IS UTILIZING STATE-OF-THE-ART MOLECULAR TECHNOLOGIES TO UNCOVER THE MULTIPLE DIMENSIONS OF MOLECULAR CHANGES THAT OCCUR IN CANCER, AND INTEGRATE THESE DATASETS TO CAPTURE A HIGH-RESOLUTION IMAGE OF THE TUMOR MOLECULAR LANDSCAPE. AMONG ICG FACULTY, THE DIVISION BOASTS AN AMAZING ARRAY OF COMPETENCIES INCLUDING GENOMIC PROFILING USING VARIOUS TECHNOLOGIES THAT INCLUDE NEXT-GENERATION SEQUENCING INCLUDING SINGLE-CELL, EPIGENETICS, NEOANTIGEN ANALYSIS, CANCER CELL BIOLOGY AND BIOINFORMATICS. ACROSS THE VARIOUS LABORATORIES, WE STUDY A MULTITUDE OF ADULT AND PEDIATRIC CANCERS, TRYING TO UNDERSTAND THE EVENTS THAT DRIVE CANCER PROGRESSION FROM PRIMARY TO ADVANCED METASTATIC DISEASE IN ADDITION TO UNDERSTANDING WHY AND HOW CANCER AFFECTS INDIVIDUALS FROM DIFFERENT ETHNICITIES AND ANCESTRAL BACKGROUNDS. ICG FACULTY ARE ALSO INVOLVED IN APPLYING HIGH-RESOLUTION GENOMIC TECHNOLOGIES TO PATIENT SAMPLES IN REAL TIME, DURING CLINICAL MANAGEMENT, TO ASSIST ONCOLOGISTS IN MAKING THERAPEUTIC RECOMMENDATIONS FOR CANCER PATIENTS. ICG IS DIRECTLY AIMING ITS EFFORTS TO DRIVE EARLIER DIAGNOSTICS AND SMARTER TREATMENTS TOWARDS PATIENTS. Form 990, Part III, Line 4b PROGRAM SERVICE DESCRIPTION NEUROGENOMICS THE NEUROGENOMICS DIVISION RESEARCH PROGRAMS SPAN ALL AGES, FROM DEVELOPMENTAL DISORDERS EARLY IN LIFE, THROUGH DISEASES OF ADULTHOOD SUCH AS NEURONAL DEGENERATION INCLUDING ALS, ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE AS WELL AS STROKE AND NEUROTRAUMA SUCH AS FROM CONCUSSION. OUR FIRST GOAL IS TO IMPROVE THE ABILITY TO DIAGNOSE NEUROLOGICAL DISEASE BEFORE IT STRIKES BY UNDERSTANDING THE INDIVIDUAL GENETIC AND EPIGENETIC VARIATION BETWEEN INDIVIDUALS. BECAUSE THESE DISEASES IMPACT SO MANY LIVES AROUND THE WORLD EITHER DIRECTLY (BY HAVING A DISEASE), OR INDIRECTLY (BY CARING FOR A LOVED ONE WITH THE DISEASE), THE SECOND GOAL CENTERS ON THE DEVELOPMENT OF NEW DRUG THERAPIES THAT SPECIFICALLY UTILIZE AN INDIVIDUAL'S GENETIC BACKGROUND. OVER THE PAST 20 YEARS, OUR INVESTIGATORS HAVE BEEN AWARDED DOZENS OF LARGE FEDERAL AND FOUNDATION GRANTS, AND DEVELOPED A RESEARCH CLINIC FOCUSED ON DIRECTLY INTERACTING WITH THE COMMUNITY AND PATIENTS IN THE AREA OF PRECISION MEDICINE. Form 990, Part III, Line 4c PROGRAM SERVICE DESCRIPTION PATHOGEN AND MICROBIOME THE PATHOGEN AND MICROBIOME DIVISION IS FOCUSED ON DEVELOPING AND TRANSLATING MICROBIAL GENOMIC DISCOVERIES INTO APPLICATION TO ADVANCE HUMAN HEALTH IN THE AREAS OF CLINICAL MEDICINE, PUBLIC HEALTH AND BIODEFENSE. THE DIVISION SEEKS TO ADVANCE OUR UNDERSTANDING OF MULTI-DRUG RESISTANT INFECTIONS, DEVELOP NOVEL GENOTYPING TECHNIQUES FOR GENOMIC EPIDEMIOLOGY AND MICROBIAL FORENSICS, FUNGAL EPIDEMIOLOGY AND PHYLOGENETICS, UNDERSTAND THE RELATIONSHIP OF MICROBES TO HUMAN HEALTH AND DISEASE, AND THROUGH THE TGEN NORTH CLIA LAB OFFER PCR AND SEROLOGY TESTING FOR SARS-COV-2. A MAJOR EMPHASIS IS ON ADAPTING AND ADVANCING NEXT-GENERATION SEQUENCING TOOLS FOR INFECTIOUS DISEASE RESEARCH AND HEALTHCARE SUCH AS DIAGNOSTIC TESTS TO CHARACTERIZE AND TRACK HOSPITAL ACQUIRED INFECTIONS, WITH AN EMPHASIS ON ANTIBIOTIC RESISTANCE, ALLOWING PHYSICIANS TO PROVIDE PERSONALIZED THERAPY AND CONTAIN OUTBREAKS. ASSAYS HAVE BEEN TAILORED TO MANY DISEASES, ORGANISMS AND SAMPLE TYPES, INCLUDING MRSA, TUBERCULOSIS, KLEB, E COLI AND STAPHYLOCOCCUS. THE DIVISION WORKS CLOSELY WITH ITS SISTER INSTITUTE AT NORTHERN ARIZONA UNIVERSITY, THE PATHOGEN AND MICROBIOME INSTITUTE, AS WELL AS WITH A NUMBER OF OTHER COLLABORATORS LOCALLY, NATIONALLY AND GLOBALLY. THE DIVISION HAS BEEN INSTRUMENTAL IN SOLVING NUMEROUS DISEASE OUTBREAKS AROUND THE WORLD, HAS GENERATED MULTIPLE INVENTIONS AND HAS LICENSED OUT INTELLECTUAL PROPERTY TO GOVERNMENTS AND BIOTECH COMPANIES. Form 990, Part III, Line 1 Organization's Mission Statement THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) IS A NONPROFIT BIOMEDICAL RESEARCH INSTITUTE FOCUSED ON DEVELOPING EARLIER AND SMARTER TREATMENTS BY EMPLOYING INNOVATIVE ADVANCES ARISING FROM THE HUMAN GENOME PROJECT AND APPLYING THEM TO THE DEVELOPMENT OF DIAGNOSTICS, PROGNOSTICS AND THERAPIES FOR CANCER, NEUROLOGICAL DISORDERS, DIABETES AND OTHER COMPLEX DISEASES. Form 990, Part III, Line 4d DESCRIPTION OF OTHER PROGRAM SERVICES OTHER SCIENCE, BY NATURE, IS AN ITERATIVE PROCESS: A QUESTION AND ANSWER CYCLE OF REFINEMENT AND FURTHER EXPERIMENTATION IN SEARCH OF MEDICAL ADVANCES, WHETHER A NEW DIAGNOSTIC TEST OR TREATMENT. IN THIS REGARD, TGEN HAS HELPED BRIDGE THE GAP BETWEEN LABORATORY DISCOVERIES AND PRACTICAL APPLICATIONS IN PATIENT CARE. OUR APPROACH HAS LED TO SIGNIFICANT STRIDES IN UNDERSTANDING DISEASES AT THE MOLECULAR LEVEL, PAVING THE WAY FOR MORE PRECISE DIAGNOSTIC TOOLS AND GROUNDBREAKING TREATMENTS. TODAY, OUR CAPACITY TO UNDERSTAND AND LEVERAGE INFORMATION FROM THE HUMAN GENOME HAS NEVER BEEN GREATER. TGEN'S ABILITY TO BRING EMERGING NEW METHODS FOR INTERROGATING A PATIENT'S GENOME INTO THE CLINICAL CARE OF PATIENTS, THE REVOLUTION IN FASTER AND LOWER-COST WAYS OF CANCER DETECTION AND THE PATHS THAT REACH THE URBAN, THE RURAL AND MORE DIVERSE POPULATIONS, HAS NEVER BEEN GREATER. THE SEQUENCE COST PER-PATIENT OVER THE PAST DECADE HAS DROPPED 100-FOLD. THIS MEANS TGEN CAN SEQUENCE MORE PATIENTS, OR SEQUENCE A PATIENT AGAIN, TO UNDERSTAND HOW THEIR DISEASE IS PROGRESSING. AS PART OF A NATIONAL HEALTH SYSTEM, THIS HELPS DRIVE RESEARCH DISCOVERY, NEW METHODS FOR EARLY DETECTION, AND MORE CLINICAL TRIALS. SEQUENCING ACCURACY HAS ALSO IMPROVED 100-FOLD. THIS INCREASED ACCURACY MEANS TGEN CAN DETECT CANCER EARLIER - PERHAPS IN ITS INFANCY - WHICH LEADS TO IMPROVED SCREENING, POST-TREATMENT MONITORING AND BIOPSIES WITH A LOW PERCENTAGE OF TUMOR PRESENT. THIS ALSO ALLOWS US TO EXPAND GENOMIC TESTING INTO MORE CANCER TYPES. WE'RE ALSO CREATING BETTER REFERENCE GENOMES, ESPECIALLY IN UNDERSERVED POPULATIONS. HAVING BETTER REFERENCES MEANS A BETTER UNDERSTANDING OF WHICH CHANGES IN THE GENOME ARE SIGNIFICANT AND TO WHICH POPULATION. Form 990, Part III, Line 4d Description of other program services (Expenses $ 35,325,500 including grants of $ 1,802,912)(Revenue $ 7,042,398) PLEASE SEE SCHEDULE O. Form 990, Part VI, Line 6 Classes of members or stockholders THE SOLE CORPORATE MEMBER OF TGEN IS CITY OF HOPE. Form 990, Part VI, Line 7a Members or stockholders electing members of governing body CITY OF HOPE, AS THE SOLE CORPORATE MEMBER OF TGEN, APPOINTS TGEN'S BOARD OF DIRECTORS. Form 990, Part VI, Line 7b Decisions requiring approval by members or stockholders CERTAIN ACTIONS MAY NOT BE UNDERTAKEN WITHOUT THE PRIOR WRITTEN APPROVAL OF THE SOLE CORPORATE MEMBER, CITY OF HOPE, AS SPECIFIED IN THE GOVERNING DOCUMENTS OF TGEN, ON BEHALF OF ITSELF OR CERTAIN AFFILIATES, BORROW OR LEND MONEY OR PLEDGE PROPERTY AS SECURITY; FIX COMPENSATION FOR DIRECTORS; CHANGE THE NUMBER OF VOTING DIRECTORS; ASSIGN, TRANSFER, PLEDGE, COMPROMISE OR RELEASE CERTAIN CLAIMS OR DEBTS; COMMENCE ASSIGNMENT FOR THE BENEFIT OF CREDITORS, PETITION FOR REORGANIZATION OR SIMILAR RELIEF OR ACTION; ACQUIRE, PURCHASE, DEVELOP, MATERIALLY IMPROVE, SELL, LEASE, OR MORTGAGE CORPORATE REAL ESTATE; MERGE, DISSOLVE OR SELL ALL OR SUBSTANTIALLY ALL ASSETS; ADOPT BUDGETS, STRATEGIC PLANS OR MATERIAL CHANGES TO OPERATIONS; FORM AFFILIATES OR MAKE BUSINESS INVESTMENTS; ADOPT, REPEAL OR AMEND KEY GOVERNING DOCUMENTS; EXERCISE CERTAIN GOVERNANCE RIGHTS; INCUR LIABILITIES OR CONTRACT OTHER THAN FOR FAIR CONSIDERATION AND IN THE ORDINARY COURSE OF BUSINESS. Form 990, Part VI, Line 8b Documentation of meetings held by committees of governing body There are no committees with the authority to act on behalf of the governing body. Form 990, Part VI, Line 11b Review of form 990 by governing body THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE TGEN FINANCE DEPARTMENT. THE FORM 990 IS THEN REVIEWED BY THE FINANCE DEPARTMENT, OTHER MEMBERS OF MANAGEMENT AND THE AUDIT AND COMPLIANCE COMMITTEE OF THE CITY OF HOPE. THE FORM 990 IS POSTED ON THE BOARD WEBSITE FOR BOARD REVIEW PRIOR TO FILING WITH THE IRS. Form 990, Part VI, Line 12c Conflict of interest policy TGEN DISTRIBUTES A CONFLICT OF INTEREST QUESTIONNAIRE ANNUALLY TO ALL DIRECTOR LEVEL POSITIONS AND ABOVE, IN ADDITION TO ANY OFFICERS AND KEY EMPLOYEES DESIGNATED BY THE CONFLICT OF INTEREST COMMITTEE. THE QUESTIONNAIRES ARE REVIEWED BY TGEN'S FINANCE DEPARTMENT AND THE OFFICE OF RESEARCH COMPLIANCE. THOSE EMPLOYEES WITH CONFLICTS ARE FURTHER REVIEWED BY THE CONFLICT OF INTEREST COMMITTEE TO ENSURE AN APPROPRIATE PLAN IS SET FORTH. UPDATES TO THE LIST ARE HANDLED ON AN AS-NEEDED BASIS, BASED ON CONTRACT REVIEWS AND EMPLOYEE INFORMATION. Form 990, Part VI, Line 15a Process to establish compensation of top management official THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE CITY OF HOPE BOARD OF DIRECTORS ("COMMITTEE"), PURSUANT TO A DELEGATION OF AUTHORITY FROM THE CITY OF HOPE BOARD OF DIRECTORS AND THE TGEN BOARD OF DIRECTORS, IS RESPONSIBLE FOR SETTING THE COMPENSATION OF THE PRESIDENT AND CEO. THE DIRECTORS ON THIS COMMITTEE ARE INDEPENDENT AND ADHERE TO A STRICT CONFLICT OF INTEREST POLICY. DELIBERATION AND DECISION MAKING ARE SUBSTANTIATED IN THE MINUTES OF THE COMMITTEE'S MEETINGS. THE MINUTES ARE REVIEWED AND APPROVED AT THE NEXT MEETING OF THE COMMITTEE. AS PART OF THE DELIBERATION PROCESS, THE COMMITTEE RECEIVES ADVICE FROM AN INDEPENDENT, THIRD-PARTY COMPENSATION CONSULTANT WITH RESPECT TO EXECUTIVE COMPENSATION, INCLUDING REVIEW OF COMPARABLE AND BENCHMARK DATA, CURRENT COMPENSATION PHILOSOPHY, STRUCTURE, AND ADMINISTRATION OF THE EXECUTIVE COMPENSATION PROGRAMS AT CITY OF HOPE AND AFFILIATES. THE COMMITTEE CARRIES OUT THE BOARD OF DIRECTORS' OVERALL RESPONSIBILITIES RELATING TO EXECUTIVE COMPENSATION. THE EXECUTIVE COMPENSATION PHILOSOPHY IS DESIGNED TO ASSIST IN ATTRACTING AND RETAINING THE CALIBER OF EXECUTIVE LEADERSHIP REQUIRED TO ENABLE CITY OF HOPE TO ACHIEVE THE HIGHEST LEVELS OF COMMUNITY BENEFIT, IMPACT TO CLINICAL CARE, QUALITY RESEARCH AND EFFICIENT PHILANTHROPIC DEVELOPMENT. UNDER THE AIP AND LTI DESCRIBED IN SCHEDULE J, A SUBSTANTIAL PORTION OF EXECUTIVE COMPENSATION IS LINKED DIRECTLY TO PERFORMANCE GOALS APPROVED IN ADVANCE. AS A RESULT, PERFORMANCE COMPENSATION MAY VARY FROM YEAR TO YEAR. GOAL SETTING UNDER THE AIP IS TIED TO ANNUAL PERFORMANCE, INCLUDING THE ATTAINMENT OF SPECIFIC BUSINESS OBJECTIVES FOR STRATEGIC AND FINANCIAL PERFORMANCE AS WELL AS NON-FINANCIAL MEASURES SUCH AS PATIENT SATISFACTION AND QUALITY OF PATIENT CARE. THE LTI IS DESIGNED TO DRIVE LONG-TERM ORGANIZATIONAL PERFORMANCE AND TRANSFORMATION BY ALIGNING EXECUTIVES WITH THE MULTI YEAR STRATEGIC PLAN AND INCENTIVIZING THEM TO ACHIEVE KEY ORGANIZATIONAL AND STRATEGIC OBJECTIVES AND GOALS. WITH THREE-YEAR VESTING PERIODS, THE LTI ALSO PROVIDES A MEANS FOR RETAINING KEY EXECUTIVE TALENT. THE COMMITTEE CONDUCTS ANNUAL COMPENSATION REVIEWS FOR THE PRESIDENT AND CEO IN DECEMBER. Form 990, Part VI, Line 15b Process to establish compensation of other employees THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE CITY OF HOPE BOARD OF DIRECTORS ("COMMITTEE") PURSUANT TO A DELEGATION OF AUTHORITY FROM THE CITY OF HOPE BOARD OF DIRECTORS, AND THE TGEN BOARD OF DIRECTORS IS RESPONSIBLE FOR SETTING THE COMPENSATION OF, OR ESTABLISHING COMPENSATION LEVELS FOR TOTAL COMPENSATION CONSISTENT WITH CITY OF HOPE'S COMPENSATION PHILOSOPHY, FOR SENIOR LEADERS AT THE SENIOR VICE PRESIDENT OR EQUIVALENT LEVEL. THE DIRECTORS ON THIS COMMITTEE ARE INDEPENDENT AND ADHERE TO A STRICT CONFLICT OF INTEREST POLICY. DELIBERATION AND DECISION MAKING ARE SUBSTANTIATED IN THE MINUTES OF THE COMMITTEE'S MEETINGS. THE MINUTES ARE REVIEWED AND APPROVED AT THE NEXT MEETING OF THE COMMITTEE. AS PART OF THE DELIBERATION PROCESS, THE COMMITTEE RECEIVES ADVICE FROM AN INDEPENDENT, THIRD-PARTY COMPENSATION CONSULTANT WITH RESPECT TO EXECUTIVE COMPENSATION, INCLUDING REVIEW OF COMPARABLE AND BENCHMARK DATA, CURRENT COMPENSATION PHILOSOPHY, STRUCTURE, AND ADMINISTRATION OF THE EXECUTIVE COMPENSATION PROGRAMS AT CITY OF HOPE AND AFFILIATES. THE COMMITTEE CARRIES OUT THE BOARD OF DIRECTORS' OVERALL RESPONSIBILITIES RELATING TO EXECUTIVE COMPENSATION. THE EXECUTIVE COMPENSATION PHILOSOPHY IS DESIGNED TO ASSIST IN ATTRACTING AND RETAINING THE CALIBER OF EXECUTIVE LEADERSHIP REQUIRED TO ENABLE CITY OF HOPE TO ACHIEVE THE HIGHEST LEVELS OF COMMUNITY BENEFIT, IMPACT TO CLINICAL CARE, QUALITY RESEARCH AND EFFICIENT PHILANTHROPIC DEVELOPMENT. UNDER THE AIP AND LTI DESCRIBED IN SCHEDULE J, A SUBSTANTIAL PORTION OF EXECUTIVE COMPENSATION IS LINKED DIRECTLY TO PERFORMANCE GOALS APPROVED IN ADVANCE. AS A RESULT, PERFORMANCE COMPENSATION MAY VARY FROM YEAR TO YEAR. GOAL SETTING UNDER THE AIP IS TIED TO ANNUAL PERFORMANCE, INCLUDING THE ATTAINMENT OF SPECIFIC BUSINESS OBJECTIVES FOR STRATEGIC AND FINANCIAL PERFORMANCE AS WELL AS NON-FINANCIAL MEASURES SUCH AS PATIENT SATISFACTION AND QUALITY OF PATIENT CARE. THE LTI IS DESIGNED TO DRIVE LONG-TERM ORGANIZATIONAL PERFORMANCE AND TRANSFORMATION BY ALIGNING EXECUTIVES WITH THE MULTI YEAR STRATEGIC PLAN AND INCENTIVIZING THEM TO ACHIEVE KEY ORGANIZATIONAL AND STRATEGIC OBJECTIVES AND GOALS. WITH THREE-YEAR VESTING PERIODS, THE LTI ALSO PROVIDES A MEANS FOR RETAINING KEY EXECUTIVE TALENT. THE COMMITTEE CONDUCTS ANNUAL COMPENSATION REVIEWS IN DECEMBER TO SET COMPENSATION LEVELS, OR WHERE THE PROPOSED COMPENSATION EXCEEDS COMPENSATION LEVELS ESTABLISHED BY THE COMMITTEE, FOR SENIOR LEADERS AT THE SENIOR VICE PRESIDENT OR EQUIVALENT LEVEL. Form 990, Part VI, Line 19 Required documents available to the public TGEN'S ARTICLES OF INCORPORATION ARE AVAILABLE TO THE PUBLIC THROUGH THE ARIZONA CORPORATION COMMISSION. TGEN'S AUDITED FINANCIAL STATEMENTS AND ITS CONFLICT OF INTEREST POLICIES ARE AVAILABLE BY WRITTEN REQUEST MADE TO THE CFO AND CONFLICT OF INTEREST DIRECTOR, RESPECTIVELY. TGEN'S BYLAWS ARE NOT MADE AVAILABLE TO THE PUBLIC. THE CENTER FOR TRANS DRUG DEVELOPMENT 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 432047329 DRUG DEVEL AZ 0 0 TGAM LLC TGEN ACCELERATORS LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 GENOMICS AZ 0 0 TGEN TRANSLATIONAL SYSTEMS LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 461309498 ADV RESEARCH AZ 474119 273370 TGEN VIDIUM LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 843319906 ANIMAL DIAG AZ 1217881 1942674 TGEN TGEN HEALTH VENTURES LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 464520712 HEALTHCARE AZ 0 35415 TGEN DROPWISE LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 811959403 RESEARCH AZ 0 7740 TGAM LLC ID ORIGINS LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 TECH TRANSFER DE 0 0 TGAM LLC PROFERO LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 LICENSING DE 0 0 TGEN METRICBIO LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 814455083 RESEARCH AZ 0 0 TGEN PMED MANAGEMENT LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 383922888 HEALTHCARE AZ 0 0 TGEN HV LLC PRECISION MEDICINE FACILITIES LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 822560090 REAL ESTATE AZ 7229400 42284389 TGEN TGEN RESEARCH INSTITUTE FOUNDATION 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 331092191 FUNDRAISING AZ 501(c)(3) 7 TGEN true CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953435919 FUNDRAISING CA 501(c)(3) 7 NA false CITY OF HOPE NATIONAL MEDICAL CENTER 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 HOSPITAL CA 501(c)(3) 3 CITY OF HOPE true BECKMAN RESEARCH INSTITUTE 1450 EAST DUARTE ROAD DUARTE CA 91010 953432210 RESEARCH CA 501(c)(3) 4 CITY OF HOPE true CITY OF HOPE MEDICAL FOUNDATION 1500 EAST DUARTE ROAD DUARTE CA 91010 272803222 HEALTHCARE CA 501(c)(3) 3 CITY OF HOPE true COH HoldCo Inc 1500 East Duarte Road Duarte CA 91010 873651176 Support DE 501(c)(3) Type III-FI City of Hope true MIDWESTERN REGIONAL MEDICAL CENTER INC 1500 EAST DUARTE ROAD DUARTE CA 91010 362510771 HOSPITAL IL 501(c)(3) 3 COH HOLDCO INC true SOUTHEASTERN REGIONAL MEDICAL CENTER INC 1500 EAST DUARTE ROAD DUARTE CA 91010 264572436 HOSPITAL GA 501(c)(3) 3 COH HOLDCO INC true WESTERN REGIONAL MEDICAL CENTER INC 1500 EAST DUARTE ROAD DUARTE CA 91010 320197974 HOSPITAL AZ 501(c)(3) 3 COH HOLDCO INC true SOUTHERN CA RADIATION ONCOLOGY 1500 EAST DUARTE ROAD DUARTE CA 91010 364887584 MGMT SERVICES CA NA N/A 0 0 false false ACCESSHOPE LLC 1500 EAST DUARTE ROAD DUARTE CA 91010 842818450 ONCOLOGY SUPPORT CA NA N/A 0 0 false false false true true false false false false false false false false true false true true false true false false CITY OF HOPE NATIONAL MEDICAL CENTER B 1802912 ACTUAL COST TGEN RESEARCH INSTITUTE FOUNDATION C 14873631 ACTUAL COST CITY OF HOPE NATIONAL MEDICAL CENTER O 1233336 ACTUAL COST TGEN RESEARCH INSTITUTE FOUNDATION Q 1217106 ACTUAL COST